Market Newsdesk

THOMASVILLE, N.C., Dec. 01, 2020 (GLOBE NEWSWIRE) — For an unprecedented eleventh consecutive year, Old Dominion Freight Line (OD) has earned the Mastio Quality Award for national less-than-truckload (LTL) carriers. The industry’s most comprehensive study ranked OD as the top carrier according to logistics professionals assessing carrier performance across 35 key attributes.

Old Dominion’s premium service stood out from other national carriers in a quantitative ranking of attributes such as “Carrier is trustworthy,” “Shipments delivered when promised,” and “Drivers are courteous and professional.” Mastio & Company’s annual survey collects LTL shippers’ responses and identifies the importance of performance factors upon carrier choice.

“In a year that brought many challenges to our industry, we are incredibly honored to be recognized by Mastio and Company for our premium service,” said Greg Gantt, President and CEO of Old Dominion Freight Line. “Our customers depend on OD to keep their promises, and we are thankful they have recognized the responsiveness, speediness, and customer focus we put into our services. This recognition is for the more than 19,000 dedicated OD team members who go above and beyond every day.”

“Carrier performance indicators are analyzed based on discussions with LTL industry customers in the annual MASTIO survey,” said Kevin Huntsman, senior vice president of Mastio & Company. “We then use all of the ‘non-cost/performance’ attributes to name the recipient of the Mastio Quality Award. For the eleventh consecutive year, we are pleased to announce Old Dominion was ranked No. 1 among national LTL carriers. They earned this distinction for being consistently rated as a top LTL carrier, preferred by their customers for any shipping needs.”

The 16th annual MASTIO study interviewed 1,576 shippers providing approximately 5,000 total observations between July and November 2020. The 2020 survey includes more than 7,800 qualitative responses and ten open-ended questions via telephone interviews with key freight decision-makers.

For more information about Old Dominion, visit www.odfl.com or call (800) 432-6335. On Twitter: @ODFL_Inc and Facebook: Old Dominion Freight Line Inc.

About Old Dominion Freight Line, Inc.

Old Dominion Freight Line, Inc. is a leading, less-than-truckload (“LTL”), union-free motor carrier providing regional, inter-regional and national LTL services through a single integrated organization. Our service offerings, which include expedited transportation, are provided through an expansive network of service centers located throughout the continental United States. Through strategic alliances, the Company also provides LTL services throughout North America. In addition to its core LTL services, the Company offers a range of value-added services including container drayage, truckload brokerage and supply chain consulting.

Kate Redding
Old Dominion Freight Line
404-266-7578
[email protected]

• New long-term safety, efficacy, and durability data for FINTEPLA® (fenfluramine) oral solution in Dravet syndrome
  
  
• Full results from
  Phase 3
  study of
  FINTEPLA in Lennox-Gastaut syndrome

• New d
  ata from investigator-initiated stud
  y
  in CDKL5
  Deficiency Disorder
  

EMERYVILLE, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) — Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, announced that data from eleven poster presentations related to FINTEPLA^® (fenfluramine) oral solution in Dravet syndrome, Lennox-Gastaut syndrome, and other rare epilepsies will be presented at the American Epilepsy Society (AES) Annual Meeting, being held virtually from December 4-8, 2020. Zogenix will also host a virtual scientific exhibition room and sponsor a continuing medical education (CME) symposium during AES 2020.

“We are honored to collaborate with leading international epilepsy experts to broaden our understanding of how FINTEPLA, a drug recently approved by the FDA to treat seizures associated with Dravet syndrome, may improve the lives of epilepsy patients and their families,” said Zogenix’s Chief Medical Officer Bradley S. Galer, M.D. “With new long-term data in Dravet syndrome, full results from our Lennox-Gastaut syndrome Phase 3 trial, and data from investigator-initiated studies, we are eager to continue advancing FINTEPLA as a potential new treatment option for additional rare epilepsies.”

Main Conference

Full data for the FINTEPLA posters presented in the main conference will be available on the AES 2020 conference site starting this Friday, December 4, at 9:00 a.m. Eastern Time and will be available after AES on the Zogenix Newsroom site. Authors will be available to discuss their data with attendees during the following times:

• Efficacy and Tolerability of Adjunctive FINTEPLA (Fenfluramine Hydrochloride) in an Open-Label Extension Study of Dravet Syndrome Patients Treated for
  U
  p to
  3 Years
  
  Scheffer, Devinsky, Perry et al
  
  Poster #978
  
  Authors available:
  Monday,
  December
  7
  ,
  1:30
  –
  3
  :
  0
  0
  P
  M
  ET
• Treatment with FINTEPLA (Fenfluramine) in Patients with Dravet Syndrome has no Long-Term Effect on Weight and Growth
  
  Gil-Nagel, Ceulemans, Wirrell et al
  
  Poster #977
  
  Authors available:
  Monday,
  December
  7
  ,
  1:30
  –
  3
  :
  0
  0
  P
  M
  ET
• Fenfluramine (FINTEPLA)
  P
  rovides Comparable Clinical Benefit in Adults and Children with Dravet Syndrome: Real-World Experience from the US Early Access Program
  
  Perry, Knupp, Wirrell, et al
  
  Poster #1057
  
  Authors available:
  Monday,
  December
  7
  ,
  1:30
  –
  3
  :
  0
  0
  P
  M
  ET
• The Long-Term Effects of Fenfluramine on Patients with Dravet Syndrome and Their Families: A Qualitative Analysis
  
  Jensen, Salem, Gammaitoni et al
  
  Poster #418
  
  Authors available:
  Sunday
  ,
  December 6, 12:00 – 1:30 PM
  ET
• University of Washington Caregiver Stress Scale Translations
  
  Amtmann, Bamer, Salem et al
  
  Poster #287
  
  Authors available: Sunday
  ,
  December 6, 12:00 – 1:30 PM
  ET
• Fenfluramine (FINTEPLA) in Dravet Syndrome: Results of a Third Randomized, Placebo-Controlled Clinical Trial
  
  Sullivan, Lagae, Cross et al
  
  Poster #853
  
  Authors available:
  Monday,
  December
  7
  ,
  9
  :00 – 1
  0
  :30
  A
  M
  ET
• Efficacy and Tolerability with FINTEPLA (Fenfluramine) in Adult Patients with Dravet Syndrome: A Case Series of Patients Participating in Phase 3 Studies
  
  Miller, Devinsky, Auvin et al
  
  Poster #849
  
  Authors available:
  Monday,
  December
  7
  ,
  9
  :00 – 1
  0
  :30
  A
  M
  ET
• Fenfluramine for the Treatment of Patients with Lennox-Gastaut Syndrome: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
  
  Knupp, Lagae, Arzimaniglou et al
  
  Poster #852
  
  Authors available:
  Monday,
  December
  7
  ,
  9
  :00 – 1
  0
  :30
  A
  M
  ET
• Fenfluramine to Treat Convulsive Seizures in Patients with CDKL5 Deficiency Disorder
  
  Devinsky, King,
  and
  Price
  
  Poster #1060
  
  Authors available:
  Monday,
  December
  7
  ,
  1:30
  –
  3
  :
  0
  0
  P
  M
  ET
  

Scientific Exhibit Room

All posters from the main conference above, plus the two additional Scientific Exhibit Room posters, will be available in the Zogenix Scientific Exhibit Room. Questions regarding data in the Scientific Exhibition Room will be answered during a live discussion on Sunday, December 6, from 8:00 – 11:00 a.m. Eastern Time.

• Impact of FINTEPLA (
  F
  enfluramine) on the Incidence Rate of SUDEP in Patients with Dravet Syndrome
  
  Cross, Galer, Gil-Nagel et al
• Fenfluramine Prevents Audiogenic Seizures in a 129/SvTer Mouse Model of Sudden Unexpected Death in Epilepsy (SUDEP)
  
  Martin, Biraben, Harnandez et al

Satellite Symposium:

Zogenix is proud to sponsor the Industry CME Satellite Symposium: An Update on Rare Childhood-Onset Epilepsies, which will be held on Sunday, December 6, from 6:00 – 7:30 p.m. Eastern Time with the following speakers and topics:

• Epileptic Encephalopathies: Phenotypic Evolution
  
  Elaine Wirrell, M.D., FRCPC
  (Program Chair)
• Mechanisms of Epileptogenesis in a Zebrafish Model of Dravet Syndrome
  
  Camila V. Esguerra, Ph
  .
  D
  .,
• An Update on Sunflower Syndrome: Clinical Features and Treatment Challenges
  
  Elizabeth
  Thiele
  , M.D., Ph.D.
• An Update on CDKL5 Deficiency Disorder: Clinical Presentations, Genetic Variation, and Approaches to Treatment
  
  Orrin
  Devinsky
  , M.D.

About Dravet Syndrome

Dravet syndrome is a rare and devastating infant-onset epilepsy highly correlated with a mutation in the SCN1A gene. The disease is marked by frequent debilitating seizures, lifelong developmental and motor impairments, and an increased risk of sudden death (SUDEP). In addition to its impact on the patient, the severity and unpredictability of the disease, coupled with around-the-clock concern for the diagnosed child’s well-being, can present significant emotional and logistical challenges for all members of the family.

About Lennox-Gastaut Syndrome

Lennox-Gastaut Syndrome (LGS) is a rare and devastating lifelong childhood-onset epilepsy that can arise from multiple different causes. LGS is characterized by many different seizure types, including many that result in frequent falls and injuries and that often don’t respond to currently available seizure medications The intellectual and behavioral problems associated with LGS, as well as around-the-clock care requirements, add to the complexity of life with this disease.

About CDKL5 Deficiency Disorder

CDKL5 deficiency disorder is a rare developmental epileptic encephalopathy caused by mutations in the CDKL5 gene. The hallmarks are early-onset, intractable epilepsy and neurodevelopmental delay impacting cognitive, motor, speech, and visual function. Although rare, it one of the most common forms of genetic epilepsy.

About FINTEPLA

^®

(fenfluramine) oral solution

FINTEPLA (fenfluramine) oral solution is approved in the United States, has received a positive CHMP opinion in Europe, and is in development in Japan for the treatment of seizures associated with Dravet syndrome, and is being investigated as a potential treatment for Lennox-Gastaut syndrome (LGS) and other rare and severe childhood-onset epilepsy disorders.

United States

IMPORTANT SAFETY INFORMATION

Boxed WARNING: VALVULAR HEART DISEASE and PULMONARY ARTERIAL HYPERTENSION

• There is an association between serotonergic drugs with 5
  ‑
  HT2B receptor agonist activity, including fenfluramine (the active ingredient in FINTEPLA), and valvular heart disease and pulmonary arterial hypertension.
• Echocardiogram assessments are required before, during, and after treatment with FINTEPLA.
• FINTEPLA is available only through a restricted program called the FINTEPLA REMS.
  

Contraindications

FINTEPLA is contraindicated in patients with hypersensitivity to fenfluramine or any of the excipients in FINTEPLA and with concomitant use of, or within 14 days of the administration of monoamine oxidase inhibitors because of an increased risk of serotonin syndrome.

WARNINGS AND PRECAUTIONS

Valvular Heart Disease and Pulmonary Arterial Hypertension (see boxed Warning)

Because of the association between serotonergic drugs with 5‑HT2B receptor agonist activity, including fenfluramine (the active ingredient in FINTEPLA), and valvular heart disease and pulmonary arterial hypertension, cardiac monitoring via echocardiogram is required prior to starting treatment, during treatment, and after treatment with FINTEPLA concludes. Cardiac monitoring via echocardiogram can aid in early detection of this condition. In clinical trials of up to 3 years in duration, no patient receiving FINTEPLA developed valvular heart disease or pulmonary arterial hypertension.

Monitoring

Prior to starting treatment, patients must undergo an echocardiogram to evaluate for valvular heart disease and pulmonary arterial hypertension. Echocardiograms should be repeated every 6 months, and once 3-6 months post-treatment with FINTEPLA.

If valvular heart disease or pulmonary arterial hypertension is observed on an echocardiogram, the prescriber must consider the benefits versus the risks of initiating or continuing treatment with FINTEPLA.

FINTEPLA REMS Program (see boxed Warning)

In the United States, FINTEPLA is available only through a restricted distribution program called the FINTEPLA REMS program. Prescribers must be certified by enrolling in the FINTEPLA REMS program. Prescribers must Counsel patients receiving FINTEPLA about the risk of valvular heart disease and pulmonary arterial hypertension, how to recognize signs and symptoms of valvular heart disease and pulmonary arterial hypertension, the need for baseline (pretreatment) and periodic cardiac monitoring via echocardiogram during FINTEPLA treatment, and cardiac monitoring after FINTEPLA treatment. Patients must enroll in the REMS program and comply with ongoing monitoring requirements. The pharmacy must be certified by enrolling in the REMS program and must only dispense to patients who are authorized to receive FINTEPLA. Wholesalers and distributors must only distribute to certified pharmacies. Further information is available at www.FinteplaREMS.com or by telephone at 1-877-964-3649.

Decreased Appetite and Decreased Weight

FINTEPLA can cause decreases in appetite and weight. Decreases in weight appear to be dose related. Most patients resumed the expected measured increases in weight by the end of the open-label extension study. Weight should be monitored regularly during treatment with FINTEPLA and dose modifications should be considered if a decrease in weight is observed.

Somnolence, Sedation, and Lethargy

FINTEPLA can cause somnolence, sedation, and lethargy. Other central nervous system (CNS) depressants, including alcohol, could potentiate these effects of FINTEPLA. Prescribers should monitor patients for somnolence and sedation and should advise patients not to drive or operate machinery until they have gained sufficient experience on FINTEPLA to gauge whether it adversely affects their ability to drive or operate machinery.

Suicidal Behavior and Ideation

Antiepileptic drugs (AEDs) increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with an AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, or any unusual changes in mood or behavior.

Anyone considering prescribing FINTEPLA or any other AED must balance the risk of suicidal thoughts or behaviors with the risk of untreated illness. Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge during treatment, consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.

Withdrawal of Antiepileptic Drugs

As with most AEDs, FINTEPLA should generally be withdrawn gradually because of the risk of increased seizure frequency and status epilepticus. If withdrawal is needed because of a serious adverse reaction, rapid discontinuation can be considered.

Serotonin Syndrome

Serotonin syndrome, a potentially life-threatening condition, may occur with FINTEPLA, particularly with concomitant administration of FINTEPLA with other serotonergic drugs, including, but not limited to, selective serotonin-norepinephrine reuptake inhibitors (SNRIs), selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), bupropion, triptans, dietary supplements (eg, St. John’s Wort, tryptophan), drugs that impair metabolism of serotonin (including monoamine oxidase inhibitors [MAOIs], which are contraindicated with FINTEPLA, dextromethorphan, lithium, tramadol, and antipsychotics with serotonergic agonist activity. Patients should be monitored for the emergence of signs and symptoms of serotonin syndrome, which include mental status changes (eg, agitation, hallucinations, coma), autonomic instability (eg, tachycardia, labile blood pressure, hyperthermia), neuromuscular signs (eg, hyperreflexia, incoordination), and/or gastrointestinal symptoms (eg, nausea, vomiting, diarrhea). If serotonin syndrome is suspected, treatment with FINTEPLA should be stopped immediately and symptomatic treatment should be started.

Increase in Blood Pressure

FINTEPLA can cause an increase in blood pressure. Significant elevation in blood pressure, including hypertensive crisis, has been reported rarely in adult patients treated with fenfluramine, including patients without a history of hypertension. Monitor blood pressure in patients treated with FINTEPLA. In clinical trials of up to 3 years in duration, no patient receiving FINTEPLA developed hypertensive crisis.

Glaucoma

Fenfluramine can cause mydriasis and can precipitate angle closure glaucoma. Consider discontinuing treatment with FINTEPLA in patients with acute decreases in visual acuity or ocular pain.

Adverse Reactions

The most common adverse reactions (incidence at least 10% and greater than placebo) were decreased appetite; somnolence, sedation, lethargy; diarrhea; constipation; abnormal echocardiogram; fatigue, malaise, asthenia; ataxia, balance disorder, gait disturbance; blood pressure increased; drooling, salivary hypersecretion; pyrexia; upper respiratory tract infection; vomiting; decreased weight; fall; status epilepticus.

Drug Interactions

Strong CYP1A2 and CYP2B6 Inducers: Coadministration with rifampin or a strong CYP1A2 and CYP2B6 inducer will decrease fenfluramine plasma concentrations.

Consider an increase in FINTEPLA dosage when coadministered with rifampin or a strong CYP1A2 and CYP2B6 inducer.

Use in Specific Populations

Administration to patients with moderate or severe renal impairment or to patients with hepatic impairment is not recommended.

Please see full Prescribing Information, including Boxed Warning, for additional important information on FINTEPLA.

About Zogenix

Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company’s first rare disease therapy, FINTEPLA^® (fenfluramine) oral solution, C-IV is approved by the U.S. FDA, has received positive CHMP opinion in Europe, and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, devastating infant-onset epilepsy. FINTEPLA is also in development for the treatment of seizures associated with Lennox-Gastaut syndrome, another rare and devastating childhood-onset epilepsy. Through its subsidiary Modis Therapeutics, Zogenix is developing MT1621, an investigational novel deoxynucleoside substrate enhancement therapy for the treatment of TK2 deficiency, a rare genetic disorder.

Forward Looking Statements

Zogenix cautions you that statements included in this press release and the poster presentations that are not a description of historical facts are forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “indicates,” “will,” “intends,” “potential,” “suggests,” “assuming,” “designed,” and similar expressions are intended to identify forward-looking statements. These statements include Zogenix’s development plans for FINTEPLA in Lennox-Gastaut syndrome (LGS) and CDKL5 deficiency disorder and for MT1621, and the potential clinical value that FINTEPLA provides for Dravet syndrome, LGS and CDKL5 deficiency disorder patients and their families. These statements are based on Zogenix’s current beliefs and expectations. The inclusion of forward-looking statements should not be regarded as a representation by Zogenix that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risks and uncertainties inherent in Zogenix’s business, including, without limitation: the timing of enrollment or results of Zogenix’s clinical trials; the COVID-19 pandemic may disrupt Zogenix’s business operations, impairing the ability to complete the planned studies of MT1621; unexpected adverse side effects or inadequate therapeutic efficacy of FINTEPLA or MT1621 that could limit development or commercialization, or that could result in recalls or product liability claims; additional data from Zogenix’s ongoing studies may contradict or undermine the data reported for Dravet syndrome or other indications; and other risks described in Zogenix’s prior press releases as well as in public periodic filings with the U.S. Securities & Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Zogenix undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

CONTACTS:

Zogenix

Melinda Baker
Senior Director, Corporate Communications
+1 (510) 788-8732
[email protected]

Investors

Brian Ritchie
Managing Director, LifeSci Advisors LLC
+1 (212) 915-2578
[email protected]

Media

Stefanie Tuck, Vice President, Porter Novelli
+1 (978) 390-1394
[email protected]

BOSTON, Dec. 01, 2020 (GLOBE NEWSWIRE) — On September 28, 2020, Interface, Inc. (NASDAQ: TILE) announced the conclusion of the long-awaited investigation by the U.S. Securities and Exchange Commission into Interface’s historical quarterly earnings per share calculations and rounding practices. Interface agreed to pay a $5 million fine to resolve the matter, and was ordered to cease-and-desist from violating the federal securities laws. On this news, shares of Interface common stock fell precipitously.

According to the Wall Street Journal, the SEC had charged Interface for reporting earnings that did not comply with the Generally Accepted Accounting Principles for multiple quarters in 2015 and 2016. Interface allegedly made unsupported, manual accounting adjustments, often when internal forecasts indicated the Company would fall short of Wall Street estimates, the SEC found. Per the SEC, Interface would then report earnings that met or exceeded those consensus estimates. In addition to the Company’s $5 million fine, two of Interface’s former executives agreed to pay penalties of $45,000 and $70,000.

A lawsuit alleging violations of federal securities laws has been filed against Interface and certain of its officers and directors. The suit alleges that beginning in March 2018, Interface misled investors by, among other things, reporting artificially inflated income and earnings per share in 2015 and 2016, failing to disclose and/or downplaying that Interface and certain of its employees were under investigation by the SEC, and having inadequate disclosure controls and procedures and internal controls over financial reporting. The lawsuit was filed in the U.S. District Court for the Eastern District of New York, and is captioned Swanson v. Interface, Inc., et al., No. 20-cv-5518.

If you purchased or acquired shares of Interface between March 2, 2018 and September 28, 2020, and have questions about your legal rights or possess information relevant to this matter, please contact Block & Leviton attorneys at (617) 398-5600, via email at [email protected], or at https://www.blockleviton.com/cases/tile. The deadline to move the Court to be appointed lead plaintiff is January 11, 2021.

Block & Leviton LLP is a firm dedicated to representing investors and maintaining the integrity of the country’s financial markets. The firm represents many of the nation’s largest institutional investors as well as individual investors in securities litigation throughout the United States. The firm’s lawyers have recovered billions of dollars for its clients.

This notice may constitute attorney advertising.

CONTACT:
BLOCK & LEVITON LLP
260 Franklin St., Suite 1860
Boston, MA 02110
Phone: (617) 398-5600
Email: [email protected] 
SOURCE: Block & Leviton LLP
www.blockleviton.com 

SAN ANTONIO, Dec. 01, 2020 (GLOBE NEWSWIRE) — Ecoark Holdings, Inc. (“Ecoark” or the “Company”) (OTC: ZEST) announced today an update on its ongoing initiative to uplist to a leading national stock exchange.

On August 17, 2020, Ecoark submitted its initial listing application to a national exchange, and on November 6, 2020, the Company filed a Form 10-Q for the fiscal quarter ended September 30, 2020 with a stockholder’s equity balance that exceeded the minimum uplisting requirements.

On November 25, 2020, the Company received feedback from an exchange representative indicating that the Company should address the voting rights implications of its Series A-1 Preferred Stock and otherwise evidence a share price that is sufficient to meet the minimum price requirements for listing on the exchange.   

In response, on November 30, 2020, the Company’s Board of Directors voted unanimously to accept the following motions:

• to redeem at cost the sole share of Series A-1 Preferred Stock issued on November 12, 2020 to Randy May, Chief Executive Officer of Ecoark;
• to revoke the entire series of Series A-1 Preferred Stock through a filing with the State of Nevada such that no additional shares of Series A-1 Preferred Stock may be issued;
• to amend the record date and meeting date of the Company’s upcoming special shareholder meeting to December 2, 2020, and December 29, 2020, respectively; and,
• to implement a 1-for-5 reverse split of its common shares, which will adjust both the Company’s total authorized and outstanding shares by the same ratio without the need for shareholder approval.

“We believe that there is significant unmet demand from institutional investors interested in accumulating Ecoark stock pending a national exchange listing and share price over $5.00,” said Randy May, Chief Executive Officer of Ecoark. “I respectfully request that our shareholders disregard any mailings they may receive for the originally planned December 16, 2020 special shareholder meeting, and instead prepare to cast their vote on December 29, 2020. With a majority vote to accept all proposed initiatives, we believe that Ecoark will have a clear path to uplist to a national stock exchange.”

Under Nevada law, the Company can effect a reverse stock split without shareholder approval by reducing its authorized common stock proportionately. Further details will be provided in a new proxy statement to be distributed in the coming days.

About Ecoark Holdings, Inc.

Founded in 2011, Ecoark is a diversified holding company. The company has three wholly-owned subsidiaries: Zest Labs, Inc. (“Zest Labs”), Banner Midstream Corp (“Banner Midstream”) and Trend Discovery Holdings (“Trend Discovery”). Zest Labs, offers the Zest Fresh™ solution, a breakthrough approach to quality management of fresh food, is specifically designed to help substantially reduce the amount of food loss the U.S. experiences each year. Banner Midstream is engaged in oil and gas exploration, production, and drilling operations on over 20,000 cumulative acres of active mineral leases in Texas, Louisiana, and Mississippi. Banner Midstream also provides transportation and logistics services and procures and finances equipment to oilfield transportation services contractors. Trend Discovery invests in a select number of early stage startups each year as part of the fund’s Venture Capital strategy; we are open-minded investors with a founder-first mentality. Trend Discovery LP has an audited track record of uncorrelated outperformance of the S&P 500 since inception.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including our expectations regarding the listing of our common stock on a national securities exchange. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. These statements are based on management’s current expectations and beliefs, as well as a number of assumptions concerning future events. Such forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other important factors, many of which are outside management’s control. Important factors that could cause actual results to differ from those in exchange’s initial listing requirements and the voting at the special shareholders meeting. Additional risks and uncertainties are identified and discussed in Ecoark’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended March 31, 2020 and the registration statement on Form S-3 filed on October 16, 2020. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Additional factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

ZEST FRESH™ and Zest Labs™ are trademarks of Zest Labs, Inc.

Contact:

Investor Relations:
John Mills
ICR                                                       
646-277-1254                                                
[email protected]

 

JERSEY CITY, NJ, Dec. 01, 2020 (GLOBE NEWSWIRE) — As part of its commitment to continuously improve the customer experience, Verisk (Nasdaq:VRSK), a leading global data analytics provider serving the insurance, energy, and financial services markets, today announced an expanded relationship with Medallia (NYSE:MDLA), a leading provider of engagement technology for customers, employees, and citizens.

With the expanded relationship, the Verisk team will have access to Medallia’s customer and employee engagement solutions, ideation crowdsourcing tool, and customer success platform. These tools will help the Verisk team more quickly understand customer trends and challenges, and identify real-time advancements that can cultivate customer value and loyalty. 

“Verisk is guided by a ‘customer first’ approach. Combining our AI technology with Medallia’s solutions will make it easier and faster for us to introduce our customers’ feedback into the design process,” said Scott Stephenson, Verisk president and CEO. “Our customer experience strategy is driven by a continual loop of product innovation, enhancement, and refinement. What better way to shape and advance our solutions than by listening to and applying insights from those who use them most?”

The expanded Medallia footprint reflects Verisk’s commitment to continuously enhance customer experience across its enterprise. With the insights gleaned from the additional analytic capabilities, Verisk will have a stronger understanding of how customers interact with its solutions, and be equipped to better serve and anticipate their needs.

“When you combine the power of a leading customer and employee experience platform, with an ideation solution and customer success tools, you have a solution set that can drive business growth, even in current times,” said Leslie Stretch, Medallia CEO. “Verisk is a recognized innovator in the data analytics space. Our work together will uncover new insights that can help Verisk make immediate improvements and provide its customers with the best experience.”

About Medallia

Medallia (NYSE:MDLA) is the pioneer and market leader in Experience Management. Medallia’s award-winning SaaS platform, the Medallia Experience Cloud, leads the market in the understanding and management of experience for customers, employees and citizens. Medallia captures experience signals created on daily journeys in person, on calls and digital channels, over video and social media and IoT interactions and applies proprietary AI technology to reveal personalized and predictive insights that can drive action with tremendous business results. Using Medallia Experience Cloud, customers can reduce churn, turn detractors into promoters and buyers, create in-the-moment cross-sell and up-sell opportunities and drive revenue-impacting business decisions, providing clear and potent returns on investment.

About Verisk

Verisk (Nasdaq:VRSK) is a leading data analytics provider serving customers in insurance, energy and specialized markets, and financial services. Using advanced technologies to collect and analyze billions of records, Verisk draws on unique data assets and deep domain expertise to provide first-to-market innovations that are integrated into customer workflows. Verisk offers predictive analytics and decision support solutions to customers in rating, underwriting, claims, catastrophe and weather risk, global risk analytics, natural resources intelligence, economic forecasting, and many other fields. Around the world, Verisk helps customers protect people, property, and financial assets. Headquartered in Jersey City, N.J., Verisk operates in 30 countries and is a member of Standard & Poor’s S&P 500® Index and part of the Nasdaq 100 Index. For more information, please visit www.verisk.com.

Contacts:

Brett Garrison
[email protected]
(917) 639-4903

Valerie Beaudett
[email protected]
(650) 400-7833

Carolyn Bass
[email protected]

STAMFORD, Conn., Dec. 01, 2020 (GLOBE NEWSWIRE) — Star Group, L.P. (the “Company” or “Star”) (NYSE: SGU), a leading home energy distributor and services provider, today announced that it will release its fiscal 2020 fourth quarter and full year results after the close of trading on December 7, 2020. Members of Star’s management team will host a webcast and conference call at 11:00 a.m. Eastern Time the following day, December 8, 2020, to review the three and twelve months ended September 30, 2020.

The webcast will be accessible on the company’s website, at www.stargrouplp.com, and the telephone number for the conference call is 877-327-7688 (or 412-317-5112 for international callers).     

About Star
Group
, L.P.

Star Group, L.P. is a full service energy provider specializing in the sale of home heating oil and propane to residential and commercial customers primarily within the Northeast, Central and Southeast United States. The Company also sells gasoline and diesel fuel as well as installs, maintains, and repairs various heating and air conditioning equipment; to a lesser extent, it provides these ancillary services outside its product customer base, including service contracts for natural gas and other heating systems. Star is the nation’s largest retail distributor of home heating oil based upon sales volume. Additional information is available by obtaining the Company’s SEC filings at www.sec.gov and by visiting Star’s website at www.stargrouplp.com, where unit holders may request a hard copy of Star’s complete audited financial statements free of charge.

Forward Looking Information

This news release includes “forward-looking statements” which represent our expectations or beliefs concerning future events that involve risks and uncertainties, including those associated with the severity and duration of the novel coronavirus, or COVID-19, pandemic, the pandemic’s impact on the U.S. and global economies, the timing, scope and effectiveness of federal, state and local governmental responses to the pandemic, the effect of weather conditions on our financial performance, the price and supply of
the products that we sell, the consumption patterns of our customers, our ability to obtain satisfactory gross profit margins, our ability to obtain new customers and retain existing customers, our ability to make strategic acquisitions, the impact of litigation, our ability to contract for our current and future supply needs, natural gas conversions, future union relations and the outcome of current and future union negotiations, the impact of current and future governmental regulations, including climate change, environmental, health, and safety regulations, the ability to attract and retain employees, customer credit worthiness, counterparty credit worthiness, marketing plans, potential cyber-attacks, general economic conditions and new technology.
All statements other than statements of historical facts included in this news release are forward-looking statements. Without limiting the foregoing, the words “believe,” “anticipate,” “plan,” “expect,” “seek,” “estimate” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking
statements are reasonable, it can give no assurance that such expectations will prove to be correct and actual results may differ materially from those projected as a result of certain risks and uncertainties. These risks and uncertainties include, but are not limited to, those set forth under the heading “Risk Factors” and “Business Strategy” in our Annual Report on Form 10- K (the “Form 10-K”) for the fiscal year ended September 30, 2019. Important factors that could cause actual results to differ materially from the Company’s expectations (“Cautionary Statements”) are disclosed in this news release and in the Form 10-Q.
Currently, one of the most significant factors, however, is the potential adverse effect of the pandemic of the novel coronavirus, or COVID-19, on the financial condition, results of operations, cash flows and performance of the Company and its customers and counterparties and the global economy and financial markets. The extent to which COVID-19 impacts us and our customers will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the scope, severity and duration of the pandemic, the actions taken to contain the pandemic or mitigate its impact, and the direct and indirect economic effects of the pandemic and containment measures, among others.
All subsequent written and oral forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by the Cautionary Statements. Unless otherwise required by law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this news release.

CONTACT:
Star Group	Chris Witty
Investor Relations	Darrow Associates, Inc.
203/328-7310	646/438-9385 or [email protected]